Brief: Spero Therapeutics Appoints Esther Rajavelu As President And Chief Executive Officer
28/04/2025 21:02
April 28 (Reuters) - Spero Therapeutics Inc SPRO.O: SPERO THERAPEUTICS APPOINTS ESTHER RAJAVELU AS PRESIDENT AND CHIEF EXECUTIVE OFFICER Source text: ID:nGNXfKwfV Further company coverage: SPRO.O (Reuters.Briefs@thomsonreuters.com)
Recent news on Spero Therapeutics
See all newsBrief: Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Spero Therapeutics - May Offer Up To $300 Million In Securities - SEC Filing
Brief: Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., As Chief Medical Officer
Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion
US FDA approves GSK's oral antibiotic for drug-resistant UTIs (updated)